Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
PURPOSE: Liver metastases represent the principal cause of death in patients with advanced colorectal cancer (CRC). Injection of resin microspheres (SIR Spheres)--containing the beta-emitter, yttrium-90--into the arterial supply of the liver can cause radioembolization of metastases. This treatment...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2007
|
| _version_ | 1797075356668133376 |
|---|---|
| author | Sharma, R Van Hazel, G Morgan, B Berry, D Blanshard, K Price, D Bower, G Shannon, J Gibbs, P Steward, W |
| author_facet | Sharma, R Van Hazel, G Morgan, B Berry, D Blanshard, K Price, D Bower, G Shannon, J Gibbs, P Steward, W |
| author_sort | Sharma, R |
| collection | OXFORD |
| description | PURPOSE: Liver metastases represent the principal cause of death in patients with advanced colorectal cancer (CRC). Injection of resin microspheres (SIR Spheres)--containing the beta-emitter, yttrium-90--into the arterial supply of the liver can cause radioembolization of metastases. This treatment has not been tested with the radiosensitizing chemotherapy, oxaliplatin, which appears synergistic in the treatment of CRC when combined with fluorouracil and leucovorin (FOLFOX). PATIENTS AND METHODS: A phase I study of SIR-Spheres therapy with modified FOLFOX4 systemic chemotherapy was conducted in patients with inoperable liver metastases from CRC who had not previously received chemotherapy for metastatic disease. Oxaliplatin (30 to 85 mg/m2) was administered for the first three cycles with full FOLFOX4 doses from cycle 4 until cycle 12. The primary end point was toxicity. RESULTS: Twenty patients were enrolled onto the study. Five patients experienced National Cancer Institute (NCI; Bethesda, MD) grade 3 abdominal pain, two of whom had microsphere-induced gastric ulcers. The dose-limiting toxicity was grade 3 or 4 neutropenia, which was recorded in 12 patients. One episode of transient grade 3 hepatotoxicity was recorded. Mean splenic volume increased by 92% following 6 months of protocol therapy. Partial responses were demonstrated in 18 patients and stable disease in two patients. Two patients underwent partial hepatic resection following protocol therapy. Median progression-free survival was 9.3 months, and median time to progression in the liver was 12.3 months. CONCLUSION: The maximum-tolerated dose was 60 mg/m2 of oxaliplatin for the first three cycles, with full FOLFOX4 doses thereafter. This chemoradiation regime merits evaluation in phase II-III trials. |
| first_indexed | 2024-03-06T23:49:18Z |
| format | Journal article |
| id | oxford-uuid:72088ddc-0226-4cb6-99a6-be1e967f17dd |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:49:18Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:72088ddc-0226-4cb6-99a6-be1e967f17dd2022-03-26T19:47:39ZRadioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:72088ddc-0226-4cb6-99a6-be1e967f17ddEnglishSymplectic Elements at Oxford2007Sharma, RVan Hazel, GMorgan, BBerry, DBlanshard, KPrice, DBower, GShannon, JGibbs, PSteward, W PURPOSE: Liver metastases represent the principal cause of death in patients with advanced colorectal cancer (CRC). Injection of resin microspheres (SIR Spheres)--containing the beta-emitter, yttrium-90--into the arterial supply of the liver can cause radioembolization of metastases. This treatment has not been tested with the radiosensitizing chemotherapy, oxaliplatin, which appears synergistic in the treatment of CRC when combined with fluorouracil and leucovorin (FOLFOX). PATIENTS AND METHODS: A phase I study of SIR-Spheres therapy with modified FOLFOX4 systemic chemotherapy was conducted in patients with inoperable liver metastases from CRC who had not previously received chemotherapy for metastatic disease. Oxaliplatin (30 to 85 mg/m2) was administered for the first three cycles with full FOLFOX4 doses from cycle 4 until cycle 12. The primary end point was toxicity. RESULTS: Twenty patients were enrolled onto the study. Five patients experienced National Cancer Institute (NCI; Bethesda, MD) grade 3 abdominal pain, two of whom had microsphere-induced gastric ulcers. The dose-limiting toxicity was grade 3 or 4 neutropenia, which was recorded in 12 patients. One episode of transient grade 3 hepatotoxicity was recorded. Mean splenic volume increased by 92% following 6 months of protocol therapy. Partial responses were demonstrated in 18 patients and stable disease in two patients. Two patients underwent partial hepatic resection following protocol therapy. Median progression-free survival was 9.3 months, and median time to progression in the liver was 12.3 months. CONCLUSION: The maximum-tolerated dose was 60 mg/m2 of oxaliplatin for the first three cycles, with full FOLFOX4 doses thereafter. This chemoradiation regime merits evaluation in phase II-III trials. |
| spellingShingle | Sharma, R Van Hazel, G Morgan, B Berry, D Blanshard, K Price, D Bower, G Shannon, J Gibbs, P Steward, W Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. |
| title | Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. |
| title_full | Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. |
| title_fullStr | Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. |
| title_full_unstemmed | Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. |
| title_short | Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. |
| title_sort | radioembolization of liver metastases from colorectal cancer using yttrium 90 microspheres with concomitant systemic oxaliplatin fluorouracil and leucovorin chemotherapy |
| work_keys_str_mv | AT sharmar radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT vanhazelg radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT morganb radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT berryd radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT blanshardk radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT priced radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT bowerg radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT shannonj radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT gibbsp radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy AT stewardw radioembolizationoflivermetastasesfromcolorectalcancerusingyttrium90microsphereswithconcomitantsystemicoxaliplatinfluorouracilandleucovorinchemotherapy |